The bone marrow transplant market is anticipated to flourish at an average CAGR of 3.4% between 2023 and 2033. The market is expected to hold a market share of USD 14.86 billion by 2033, while the market is likely to reach a value of USD 10.65 billion in 2023. A historical CAGR of 2.5% has been recorded by the experts of Future Market Insights for the market concerned.
The hematopoietic stem cell is a soft vascular tissue in the interiors of long bones, and a bone marrow transplant is identified as the procedure to replace the damaged or destroyed bone marrow with healthy bone marrow stem cells.
| Attributes | Details |
|---|---|
| Bone Marrow Transplant Market CAGR (2023 to 2033) | 3.4% |
| Bone Marrow Transplant Market Size (2023) | USD 10.65 billion |
| Bone Marrow Transplant Market Size (2033) | USD 14.86 billion |
The bone marrow transplant procedure is prescribed for the treatment of advanced stages of leukemia, Hodgkin, and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia, and other diseases. Increasing awareness, combined with an increase in initiatives run by healthcare practitioners, is majorly responsible for the global growth of the market.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The market is anticipated to have mixed dynamics contributing to the bearish propulsion of the bone marrow transplant market. Several factors impacting the expansion of the market are identified during the study.
Besides the factors influencing growth, it is also identified that certain aspects can limit growth and curb the pace of growth further in the market.
Drivers:
Restraints:
| Country | Revenue Share % (2022) |
|---|---|
| United States | 30.3% |
| Germany | 11.9% |
| Japan | 2/0% |
| North America | 32.3% |
| Europe | 53.1% |
| Country | CAGR % (2023 to 2033) |
|---|---|
| China | 4.2% |
| India | 3.4% |
| United Kingdom | 2.4% |
| Australia | 3.1% |
North America is projected to secure steady bone marrow transplant market growth during the forecast period. The region cumulatively held 32.3% market share of the global bone marrow transplant market in 2022.
The factors attributing to the growth can be mentioned as follows:
Europe is projected to dominate the global market for bone marrow transplants during the forecast period. At present, Europe holds 53.1% of the total market share for bone marrow transplants worldwide in 2022.
The reasons owing for such extensive market expansion are mentioned below:
| Category | By Transplant Type |
|---|---|
| Leading Segment | Autologous |
| Market Share (2022) | 54.5% |
| Category | By End User |
|---|---|
| Leading Segment | Hospital |
| Market Share (2022) | 90.3% |
The start-ups in the bone marrow transplant market are indulging in collaborations and continually making innovations to stem cell transplant procedures to further make it convenient and cost-efficient for the population.
| Company Name | Magenta Therapeutics, Cambridge (United States) |
|---|---|
| Total Funding | USD 151 million |
| Description | Developed stem cell-based therapies for autoimmune disease, genetic blood disorders, and cancer. The company has developed stem cell transplants by using targeted antibodies, stem cell harvesting using new biologic agents, and increasing stem cell numbers by targeting self-renewal pathways. |
| Company Name | Kiadis Pharma, Amsterdam (Netherlands) |
|---|---|
| Total Funding | USD 33 million |
| Description | Kiadis Pharma is a developer of therapeutic solutions for hematopoietic stem cell transplants. It is focused on developing solutions for complications and limitations of hematopoietic stem cell transplants (HSCT) in blood cancer patients. The company uses all depleted T-cell immunotherapeutics (ATIR) to support the patient’s newly transplanted immune system before it becomes fully functional. This enables better acceptance of even haploidentical (or lower) stem cell donors. Kiadis is investigating the use of ATIR in leukemia and thalassemia. |
| Company Name | Talaris, Boston |
|---|---|
| Total Funding | USD 215 million |
| Description | Talaris Therapeutics is involved in developing single-dose cell therapy to treat living donor kidney transplant tolerance. They have developed a proprietary technology that allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs). The lead candidate, FCR001, is in phase III clinical trial, which is being investigated for living donor kidney transplant tolerance. |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The bone marrow transplant market is highly competitive and consists of several leading players. To increase their global market presence, market leaders are engaging in various product launches, mergers and acquisitions, and development activities focusing on orthopedic surgical treatments.
Recent Developments
Some Recent Developments Identified in the Analysis are:
The market is anticipated to be valued at USD 10.65 billion in 2023.
The global market advanced at a 2.5% HCAGR from 2018 to 2022.
Up until 2033, the market is anticipated to thrive at a CAGR of 3.4%.
Potentially holding 32.3% of the market in North America.
The market has been dominated by Europe, 53.1%.
By 2033, the market is anticipated to be worth USD 14.86 billion.
The autologous category to escalate to a market share of 54.5% in 2023.
| Market Size, 2024 | USD 16.7 billion |
|---|---|
| Projected Market Size, 2034 | USD 52.1 billion |
| Value-based CAGR (2024 to 2034) | 12.1% |
| Market Size (2022E) | USD 3.2 Billion |
|---|---|
| Projected Market Value (2032F) | USD 6.3 Billion |
| Market CAGR (2022 to 2032) | 7.1% |
Explore Healthcare Services Insights
View Reports
Bone Marrow Transplant Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
